Provisional Consent to the Distribution of a New Medicine Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto: Schedule Name and Strength Form Name and Address of Manufacturer Proprietary Name(if any) Carmustine 7.7 mg Implant, intracranial Guilford Pharmaceuticals Inc., Baltimore, Maryland, United States of America Gliadel Note: This consent is valid for 2 years from the date of publication of this notice. Dated this 19th day of May 1999. G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on the 20th day of February 1997.